HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy

Journal of Immunology

Volumn 168, Issue 11, 2002, Pages 5900-5906

  Scardino, Antonio ^a   Gross, David Alexandre ^a   Alves, Pedro ^a   Schultze, Joachim L ^a   Graff Dubois, Stéphanie ^a   Faure, Olivier ^a   Tourdot, Sophie ^a   Chouaib, Salem ^a   Nadler, Lee M ^a   Lemonnier, François A ^a   Vonderheide, Robert H ^a   Cardoso, Angelo A ^a   Kosmatopoulos, Kostas ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL;

EID: 0036604430     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.168.11.5900     Document Type: Article

References (42)

1. Genes coding for tumor antigens recognized by cytolytic T lymphocytes
2. Human tumor antigens recognized by T cells
3. HER-2/neu protein: A target for antigen specific immunotherapy of human cancer
4. hEst2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization
5. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
6. HER-2/neu signal transduction in human breast and ovarian cancer
7. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
8. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
9. Specific association of human telomerase activity with immortal cells and cancer
10. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
11. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans
12. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor specific cytotoxic T lymphocytes lines
13. The HER-2/neu derived peptide p654-662 is a tumor associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes
14. Tumor specific and HLA A2 restricted cytolysis by tumor associated lympocytes in human metastatic breast cancer
15. HER-2/neu derived peptides are tumor associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes
16. HER-2/neu derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer
17. Identification of new HER-2/neu derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas
18. Identification of novel HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other epithelial tumors
19. Identification of new epitopes from four different tumor associated antigens: Recognition of naturally processed epitopes correlates with HLA-A*0201 binding affinity
20. Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes
21. Tolerance to p53 by A2.1 restricted cytotoxic T lymphocytes
22. The use of HLA A2.1/p52 peptide tetramers to visualize the impact of self-tolerance on the TCR repertoire
23. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: Implications for tumor immunotherapy
24. Avoiding tolerance against prostatic antigens with subdominant peptide epitopes
25. Gp100/pmel 17 is a murine tumor rejection antigen: Induction of self-reactive tumoricidal T cells using high-affinity, altered peptide ligand
26. Hierarchy, tolerance, and dominance in the antitumor T-cell response
27. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants
28. Induction of anti-self-immunity to cure cancer
29. A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: Implication in the identification of cryptic tumor epitopes
30. 2m double knockout mice
31. CD40-activated human B cells: An alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy
32. Scheme for ranking potential HLA A2 binding peptides based on independent binding of individual peptide side chains
33. The relationship between class 1 binding affinity and immunogenicity of cytotoxic T cell epitopes
34. Heteroclitic immunization induces tumor immunity
35. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy
36. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy
37. Chimeric peptides: A new approach to enhance immunogenicity of peptides with low MHC binding affinity: Application in antiviral protection
38. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination
39. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes
40. H-2 class I knockout, HLA-A2.1-transgenic mice: A versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies
41. Evidence that a single peptide MHC complex on a target cell can elicit a cytotoxic T cell response
42. Protection against lethal viral infection by vaccination with non-immunodominant peptides